{
  "resourceType" : "CodeSystem",
  "id" : "heartland-evidence-level",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Narrativa gerada: CodeSystem heartland-evidence-level</b></p><a name=\"heartland-evidence-level\"> </a><a name=\"hcheartland-evidence-level\"> </a><p>Este case-sensitive sistema de código <code>https://fhir.heartlandprotocol.org/CodeSystem/heartland-evidence-level</code> define o seguinte códigos:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Código</b></td><td><b>Ecrã</b></td><td><b>Definição</b></td></tr><tr><td style=\"white-space:nowrap\">established<a name=\"heartland-evidence-level-established\"> </a></td><td>Established Evidence</td><td>Interventions with strong guideline support, such as SGLT2i for all HF phenotypes endorsed by the 2022 AHA/ACC/HFSA guideline.</td></tr><tr><td style=\"white-space:nowrap\">emerging<a name=\"heartland-evidence-level-emerging\"> </a></td><td>Emerging Evidence</td><td>Recent trial findings not yet fully incorporated into guidelines, such as finerenone for HFpEF based on the FINEARTS-HF trial.</td></tr><tr><td style=\"white-space:nowrap\">pragmatic<a name=\"heartland-evidence-level-pragmatic\"> </a></td><td>Pragmatic Heuristic</td><td>Tools developed for clinical utility without formal statistical validation, such as the HEARTLAND Risk Score itself.</td></tr></table></div>"
  },
  "url" : "https://fhir.heartlandprotocol.org/CodeSystem/heartland-evidence-level",
  "version" : "0.1.0",
  "name" : "HeartlandEvidenceLevel",
  "title" : "HEARTLAND Evidence Level",
  "status" : "active",
  "experimental" : false,
  "date" : "2026-04-16T20:13:50-04:00",
  "publisher" : "Vicky Muller Ferreira, MD",
  "contact" : [{
    "name" : "Vicky Muller Ferreira, MD",
    "telecom" : [{
      "system" : "url",
      "value" : "https://heartlandprotocol.org"
    },
    {
      "system" : "email",
      "value" : "vickymuller@heartlandprotocol.org"
    }]
  },
  {
    "name" : "Vicky Muller Ferreira, MD",
    "telecom" : [{
      "system" : "email",
      "value" : "vickymuller@heartlandprotocol.org",
      "use" : "work"
    },
    {
      "system" : "url",
      "value" : "https://heartlandprotocol.org"
    }]
  }],
  "description" : "Three-tiered transparency labels distinguishing evidence strength behind HEARTLAND Protocol v3.2 recommendations, helping clinicians calibrate clinical decisions.",
  "jurisdiction" : [{
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "code" : "US"
    }]
  }],
  "copyright" : "CC-BY 4.0",
  "caseSensitive" : true,
  "content" : "complete",
  "count" : 3,
  "concept" : [{
    "code" : "established",
    "display" : "Established Evidence",
    "definition" : "Interventions with strong guideline support, such as SGLT2i for all HF phenotypes endorsed by the 2022 AHA/ACC/HFSA guideline."
  },
  {
    "code" : "emerging",
    "display" : "Emerging Evidence",
    "definition" : "Recent trial findings not yet fully incorporated into guidelines, such as finerenone for HFpEF based on the FINEARTS-HF trial."
  },
  {
    "code" : "pragmatic",
    "display" : "Pragmatic Heuristic",
    "definition" : "Tools developed for clinical utility without formal statistical validation, such as the HEARTLAND Risk Score itself."
  }]
}